Sophia Tsoka Selected Research

Antibodies

1/2023	B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma.
1/2022	Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies.
1/2020	B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.
5/2019	IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states.
1/2017	Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sophia Tsoka Research Topics

Disease

11	Neoplasms (Cancer) 03/2023 - 01/2017
8	Melanoma (Melanoma, Malignant) 01/2023 - 01/2012
4	Inflammation (Inflammations) 06/2022 - 12/2010
3	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 01/2017
2	Autoimmune Diseases (Autoimmune Disease) 01/2023 - 02/2014
2	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2017
2	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2017
2	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2014 - 09/2012
1	Colorectal Neoplasms (Colorectal Cancer) 03/2023
1	Adenocarcinoma 06/2022
1	Triple Negative Breast Neoplasms 01/2021
1	Bacterial Infections (Bacterial Infection) 11/2020
1	Dysbiosis 10/2019
1	Atopic Dermatitis (Atopic Eczema) 10/2019
1	Sarcoma (Soft Tissue Sarcoma) 01/2017
1	Neuroblastoma 01/2017
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2017
1	Mesothelioma 01/2017
1	Pruritus (Itching) 01/2016
1	Hypoxia (Hypoxemia) 06/2011
1	Myocardial Stunning (Stunned Myocardium) 06/2011
1	Acquired Immunodeficiency Syndrome (AIDS) 06/2011

Drug/Important Bio-Agent (IBA)

5	AntibodiesIBA 01/2023 - 01/2017
5	CytokinesIBA 01/2022 - 12/2010
4	Immunoglobulin E (IgE)IBA 01/2023 - 01/2017
4	AntigensIBA 01/2023 - 01/2019
4	Monoclonal AntibodiesIBA 01/2022 - 02/2014
2	chondroitin sulfate proteoglycan 4IBA 01/2023 - 01/2017
2	Fc Receptors (Fc Receptor)IBA 01/2023 - 01/2017
2	Complementarity Determining Regions (Complementarity Determining Region)IBA 01/2023 - 01/2021
2	Immune Checkpoint ProteinsIBA 01/2022 - 01/2021
2	Immunoglobulin G (IgG)IBA 01/2021 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 10/2019
1	SolutionsIBA 03/2023
1	AutoantigensIBA 01/2023
1	Folate Receptor 1IBA 01/2023
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 06/2022
1	Filaggrin ProteinsIBA 06/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	PlasticsIBA 01/2022
1	Galectins (Galectin)IBA 01/2022
1	Immunoglobulin A (IgA)IBA 01/2021
1	Death Domain ReceptorsIBA 01/2021
1	pembrolizumabIBA 01/2021
1	NivolumabIBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Immunoglobulin D (IgD)IBA 01/2021
1	IpilimumabIBA 01/2021
1	cyclopropapyrroloindoleIBA 01/2020
1	Tryptophan (L-Tryptophan)FDA Link 10/2019
1	HaptoglobinsIBA 01/2019
1	ApolipoproteinsIBA 01/2019
1	Antiparasitic Agents (Antiparasitics)IBA 01/2017
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2017
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2017
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 02/2014
1	Interleukin-22 (IL-22)IBA 02/2014
1	Proteins (Proteins, Gene)FDA Link 06/2011
1	ProteomeIBA 06/2011

Therapy/Procedure

5	Immunotherapy 01/2023 - 01/2012
4	Therapeutics 01/2023 - 09/2012